In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Corcept Therapeutics (CORT – Research Report). The company’s shares closed last Friday at $23.23.
According to TipRanks, Lee is a 5-star analyst with an average return of 29.6% and a 53.70% success rate. Lee covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Corcept Therapeutics, and Crispr Therapeutics AG.
Corcept Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $39.00.
See today’s best-performing stocks on TipRanks >>
CORT market cap is currently $2.4B and has a P/E ratio of 24.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corcept Therapeutics (CORT) Company Description:
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
Read More on CORT:
- Bad News for Corcept Therapeutics Stock: This New Risk Has Been Added
- Corcept Therapeutics price target raised to $42 from $36 at Truist
- Corcept Therapeutics price target raised to $38 from $28 at H.C. Wainwright
- Corcept Therapeutics announces preliminary results from CATALYST study
- Corcept Therapeutics reports Q4 EPS 28c, consensus 26c
